Paper Details

  1. Home
  2. Paper Details

Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.

Author: FarewellVern, HeslinMargaret, IbrahimFowzia, KingsleyGabrielle, MaMargaret, O'KeeffeAidan G, PatelAnita, ScottDavid L, WalkerDavid

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combination disease-modifying antirheumatic drugs (cDMARDs) were found to be as effective as tumor necrosis factor inhibitors (TNFis) in treating rheumatoid arthritis (RA), but at a lower cost. Patients who initially received cDMARDs experienced greater reductions in HAQ scores and increases in EQ-5D scores at 12 months. Both cDMARDs and TNFis resulted in similar rates of DAS28 remission.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Rheumatoid arthritis (RA) is initially treated with methotrexate and other disease-modifying antirheumatic drugs (DMARDs). Active RA patients who fail such treatments can receive tumour necrosis factor inhibitors (TNFis), which are effective but expensive. OBJECTIVE: We assessed whether...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780958/

データ提供：米国国立医学図書館（NLM）

TNF Inhibitors vs. Combination Intensive Therapy for Rheumatoid Arthritis: The TACIT Trial

This study, like a desert researcher meticulously studying the impact of a changing climate, examines the effectiveness of tumor necrosis factor inhibitors (TNFis) compared to combination disease-modifying antirheumatic drugs (cDMARDs) for treating rheumatoid arthritis (RA). The TACIT trial, a randomized controlled trial, compared the clinical benefits and cost-effectiveness of these two treatment approaches. The results suggest that cDMARDs may be a viable and cost-effective alternative to TNFis for treating RA.

cDMARDs: A Potentially Cost-Effective Alternative for Rheumatoid Arthritis

This study, like a caravan discovering a new trade route, explores the potential of cDMARDs as a cost-effective alternative to TNFis for treating RA. The TACIT trial found that cDMARDs were associated with similar clinical benefits but significantly lower costs. This finding holds promise for improving access to effective treatments for RA while also considering the economic burden of managing this chronic disease.

Managing Rheumatoid Arthritis: Finding the Right Balance

This study, like a desert oasis providing a sanctuary for weary travelers, highlights the importance of finding the right treatment approach for RA. The research suggests that cDMARDs may be a viable and cost-effective option for many patients, but further research is needed to determine the best approach for each individual. It's a reminder that the journey of managing RA requires a personalized approach, considering both clinical effectiveness and economic factors.

Dr. Camel's Conclusion

The TACIT trial provides valuable insights into the effectiveness and cost-effectiveness of cDMARDs compared to TNFis for treating RA. This research offers a potential path towards more affordable and accessible treatment options for this chronic condition. It's a reminder that finding the right balance between clinical effectiveness and cost-effectiveness is crucial for managing chronic diseases effectively.

Date :
  1. Date Completed 2015-07-08
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

25351370

DOI: Digital Object Identifier

PMC4780958

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.